OS Therapies (NYSE:OSTX) Given "Buy" Rating at D. Boral Capital

Key Points

• OS Therapies has received a "buy" rating from D. Boral Capital, along with a target price of $20.00 for the stock.
• Recently, OS Therapies' stock traded down 2.6%, reaching $2.25, with a market capitalization of $71.20 million.
• Several large investors have increased their stakes in OS Therapies, with CM Management LLC raising its position by 172.6% in the first quarter.

D. Boral Capital restated their buy rating on shares of OS Therapies (NYSE:OSTX - Free Report) in a research report report published on Friday,Benzinga reports. The brokerage currently has a $20.00 price objective on the stock.

OS Therapies Stock Down 0.2%

OSTX traded down $0.01 during trading on Friday, hitting $2.22. 129,829 shares of the company's stock were exchanged, compared to its average volume of 714,071. The business's 50 day moving average is $1.98 and its two-hundred day moving average is $1.78. OS Therapies has a fifty-two week low of $1.12 and a fifty-two week high of $7.00. The stock has a market cap of $70.09 million and a P/E ratio of -2.80.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OSTX. Bridgeway Capital Management LLC acquired a new position in OS Therapies during the second quarter worth $47,000. XTX Topco Ltd acquired a new position in OS Therapies during the second quarter worth $63,000. Finally, CM Management LLC raised its holdings in OS Therapies by 172.6% during the first quarter. CM Management LLC now owns 300,000 shares of the company's stock worth $462,000 after buying an additional 189,956 shares during the last quarter.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.